Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes-Reference-Cited by-同舟云学术

Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes

Published:2009-04 Issue:2 Volume:8 Page:197-206
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Sylvester John E.,Grimm Peter D.,Eulau Stephen M.,Takamiya Robert K.,Naidoo Devi

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference23 articles.

1. Transperineal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography;Holm;J Urol,1983

2. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance;Blasko;Endocuriether Hyperthermia Oncol,1987

3. Interstitial implantation techniques in prostate cancer;Sylvester;J Surg Oncol,1997

4. Palladium-103 brachytherapy for prostate carcinoma;Blasko;Int J Radiat Oncol Biol Phys,2000

5. Ten year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy;Grimm;Int J Radiat Oncol Biol Phys,2001

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage Re-irradiation Therapy After Loco-regional Failure for Radiotherapy;Salvage Therapy for Prostate Cancer;2020-11-24

2. The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance;Brachytherapy;2020-11

3. Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer;Journal of Contemporary Brachytherapy;2020

4. Accurate and robust deep learning-based segmentation of the prostate clinical target volume in ultrasound images;Medical Image Analysis;2019-10

5. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial;Brachytherapy;2018-11